<DOC>
	<DOCNO>NCT01424839</DOCNO>
	<brief_summary>STUDY DESIGN : Prospective , non-randomised multicentre study patient stratify accord risk group INVESTIGATIONAL MEDICINAL PRODUCTS The IMPs trial Carboplatin , Cisplatin , Ifosfamide Etoposide ( approved German competent authority ) . PRIMARY OBJECTIVES : Germinoma - To maintain current high event-free survival ( EFS ) rate use risk adapt approach - In localised germinoma : omit whole brain spinal irradiation use combine treatment standard chemotherapy ventricular irradiation ( +/- boost ) - In bifocal tumour ( pineal + suprasellar ) : treat non-metastatic disease omit whole brain spinal irradiation use combine treatment standard chemotherapy ventricular irradiation ( +/- boost ) - In metastatic disease : maintain current excellent EFS metastatic germinoma craniospinal irradiation Malignant non-germinoma To improve EFS : - dose escalation chemotherapy patient identify high risk diagnosis ( age &lt; 6 year and/or AFP serum / CSF &gt; 1000 ng/ml ) - standardise surgical approach residual disease treatment Teratoma - To register patient collect data regard diagnostics , treatment outcome order develop future treatment strategy SECONDARY OBJECTIVES : Germinoma - To minimise long term effect irradiation spar spinal whole brain radiotherapy non-metastatic disease Malignant non-germinoma - In standard risk maintain EFS chemotherapy local irradiation Teratoma - To evaluate influence surgery treatment outcome assist development fu-ture treatment strategy For histological subtypes - To improve accuracy diagnosis stag register patient - To standardise neurosurgical intervention - For patient require biopsy resection accord protocol guideline , collect store tumour material , CSF possible , use future biological study . ENDPOINTS / Criteria evaluation : Main end point Event-free survival , define minimum time date diagnosis : - Death cause - Relapse - Progressive disease therapy - Or second malignancy Secondary end point - Overall survival , define time death cause , measure date diagnosis - Short long term toxicity .</brief_summary>
	<brief_title>Prospective Trial Diagnosis Treatment Intracranial Germ Cell Tumors</brief_title>
	<detailed_description>PATIENT POPULATION Age patient : low upper age limit ; Estimated number : 400 malignant germ cell tumours Diagnosis main criterion inclusion/exclusion : Intracranial Germ Cell tumours histology intracranial site dissemination Inclusion criterion - Main residence one participating country - Primary diagnosis intracranial germ cell tumour - Written consent trial participation , treatment accord protocol consent data trans-fer Exclusion criterion : - Tumour entity primary intracranial germ cell tumour CNS GCT second malignancy - Primary diagnosis pre-dating open SIOP CNS GCT II participate country registration - Medical , psychiatric social condition incompatible trial treatment treatment accord protocol intend - Participation within different trial treatment germ cell tumours and/or concurrent treatment within clinical trial . The exception trial different endpoint , involve aspect supportive treatment run parallel SIOP CNS GCT II without influence outcome trial e.g . trial antiemetic , antimycotic , antibiotic , strategy psychosocial support etc . - Pregnancy lactation - Any treatment give accord protocol prior registration TREATMENT : GERMINOMA Chemotherapy : - Non-metastatic fully stag germinoma ( ± teratoma ) Two course ( 1 3 ) Etoposide Carboplatin , alternate two course ( 2 4 ) Etoposide Ifosfamide Note : Bifocal germinoma ( pineal+suprasellar ) treat non-metastatic germinoma , stag-ing show additional dissemination - Metastatic incompletely stag germinomas ( ± teratoma ) Do receive chemotherapy protocol Radiotherapy : - Non-metastatic pure germinoma PR/SD After Chemotherapy : 24 Gy ( 15 fraction ) whole ventricle 16 Gy ( 10 fraction ) boost tumour bed ( total tumour dose 40 Gy ) - Non-metastatic germinoma CR After Chemotherapy : 24 Gy ( 15 fraction ) whole ventricle - Metastatic incompletely stag pure germinoma 24 Gy ( 15 fraction ) craniospinal axis 16 Gy ( 10 fraction ) boost tumour bed intracranial metastasis spinal deposit ( total tumour dose 40 Gy ) - Non-metastatic germinoma plus teratoma ( incompletely resect ) After Chemotherapy : 24 Gy ( 15 fraction ) whole ventricle ; 30.4 Gy ( 19 fraction ) boost tumour bed ( total tumour dose 54.4 Gy ) - Metastatic germinoma plus teratoma ( incompletely resect ) 24 Gy ( 15 fraction ) craniospinal axis ; 30.4 Gy ( 19 fraction ) boost tumour bed 16 Gy ( 10 frac-tion ) boost metastasis ( total tumour dose 54.4 Gy ) NON-GERMINOMA ( ± TERATOMA ) Chemotherapy : - Standard risk non-germinomatous malignant GCT Four course Etoposide , Cisplatin Ifosfamide ( standard treatment ) - High risk non-germinomatous malignant GCT Two course standard Etoposide , Cisplatin Ifosfamide , follow two dose intensified course Etoposide , Cisplatin Ifosfamide stem cell support Resection residual tumour 3 course chemotherapy ( indicate ) , follow : 4th course . If vi-able cell find resect tumour specimen patient transfer high risk arm Radiotherapy standard high risk non-germinomatous malignant GCT : - Patients localised disease diagnosis After Chemotherapy : 54 Gy focal radiotherapy 30 fraction - Patients metastatic disease diagnosis After Chemotherapy : 30 Gy ( 20 fraction ) craniospinal axis 24 Gy ( 15 fraction ) boost tumour site intracranial metastasis ( total tumour dose 54 Gy ) 20.8 Gy ( 13 fraction ) boost spinal deposit ( total dose 50.8 Gy ) SPECIAL ASPECTS : Central response evaluation national basis : Germinoma : In patient localised germinoma central national radiological review mandatory response evaluation chemotherapy decision ventricular irradiation additional tu-mour boost perform . Non-Germinoma : After three course chemotherapy evaluate response treatment deter-mine necessity surgery case residual radiotherapy .</detailed_description>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Main residence one participating country Primary diagnosis intracranial germ cell tumour Written consent trial participation , treatment accord protocol consent data transfer Tumour entity primary intracranial germ cell tumour CNS GCT second malignancy Primary diagnosis predate open SIOP CNS GCT II participate country registration Medical , psychiatric social condition incompatible trial treatment treatment accord protocol intend Participation within different trial treatment germ cell tumours and/or concurrent treatment within clinical trial . The exception trial different endpoint , involve aspect supportive treatment run parallel SIOP CNS GCT II without influence outcome trial e.g . trial antiemetic , antimycotic , antibiotic , strategy psychosocial support etc . Pregnancy lactation Any treatment give accord protocol prior registration</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>SIOP CNS GCT II</keyword>
	<keyword>Patients primary disease Intracranial Germ Cell Tumors</keyword>
</DOC>